Keeping viral load at a lower level when starting PD-1 therapy is therefore not necessary if antiviral therapy is also available, and a high viral load should not be a contraindication to PD-1/PD-L1 ICI therapy in patients with HBV-related liver cancer. This evidence concerns the gene CD274 and liver cancer.